Related Experiment Video
Updated: Nov 16, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1
Daniele Santini1, Marco Stellato1,2, Ugo De Giorgi3
1Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.
Objectives:
The aim of our study was to collect data about of the outcome of metastatic renal cell carcinoma patients who progressed after immune checkpoint inhibitors in order to enhance data about efficacy and safety of treatment beyond immune-oncology (IO).
Materials And Methods:
A total of 162 eligible patients, progressing to IO, were enrolled from 16 Italian referral centers adhering to the Meet-Uro association. Baseline characteristics, outcome data and toxicities were retrospectively collected. Descriptive analysis was made using median values and ranges. Kaplan-Meier method and Mantel-Haenszel log-rank test were performed to compare differences between groups.
Results:
A total of 111 patients (68.5%) were treated after IO progression. In all, 51 patients (31.5%) did not receive further treatment for clinical deterioration. Median IO progression free survival (PFS) was 4 months (95% confidence interval [CI]: 3.1-4.8). IO-PFS tends to be longer in patients reporting adverse events (AE) of any grade (5.03 [95% CI: 3.8-6.1] vs. 2.99 [95% CI: 2.4-3.5] months P=0.004). Subsequent therapies included cabozantinib (n=79, 48%), everolimus (n=11, 6.7%), and others (n=21, 12.9%).Median PFS post-IO was 6.5 months (95% CI: 5.1-7.8). Cabozantinib showed longer PFS compared with everolimus (7.6 mo [95% CI: 5.2-10.1] vs. 3.2 mo [95% CI: 1.8-4.5]) (hazard ratio: 0.2; 95% CI: 0.1026-0.7968) and other drugs (4.3 mo [95% CI: 1.3-7.4]) (hazard ratio: 0.6; 95% CI: 0.35-1.23). All grade AE were reported in 83 patients (74%) and G3 to G4 AE in 39 patients (35%). Target therapies post-IO showed median overall survival of 14.7 months (95% CI: 0.3-21.4).
Conclusions:
In our real world experience after progression to IO, vascular endotelial groth factor-tyrosine kinase inhibitors, given to patients, proved to be active and safe choices. Cabozantinib was associated with a better outcome in terms of median PFS.
Insights
In metastatic renal cell carcinoma patients progressing after immune checkpoint inhibitors, subsequent therapies like cabozantinib demonstrated efficacy and safety. Cabozantinib showed improved progression-free survival compared to other treatments.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic renal cell carcinoma (mRCC) treatment has evolved with immune checkpoint inhibitors (IO).
- Limited data exists on outcomes for patients progressing after IO therapy.
- Understanding post-IO treatment efficacy and safety is crucial for clinical decision-making.
Purpose of the Study:
- To evaluate the efficacy and safety of treatments beyond immune-oncology (IO) in mRCC patients who progressed after IO.
- To collect real-world data on subsequent therapies and their outcomes.
Main Methods:
- Retrospective analysis of 162 mRCC patients from 16 Italian centers who progressed on IO.
- Data collected included baseline characteristics, outcomes, and toxicities.
- Kaplan-Meier and Mantel-Haenszel log-rank tests were used for survival analysis.
Main Results:
- 111 patients received subsequent therapies; 51 did not. Median IO progression-free survival (PFS) was 4 months.
- Cabozantinib (48%) showed longer PFS (7.6 months) compared to everolimus (3.2 months) and other drugs (4.3 months).
- Overall survival post-IO targeted therapies was 14.7 months, with 74% experiencing adverse events.
Conclusions:
- Vascular endothelial growth factor-tyrosine kinase inhibitors are active and safe options post-IO progression in mRCC.
- Cabozantinib demonstrated superior progression-free survival in this patient cohort.
- Real-world data supports the use of targeted therapies beyond IO in advanced RCC.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020